Charles River Laboratories International (NYSE:CRL) Shares Gap Down – Should You Sell?

Shares of Charles River Laboratories International, Inc. (NYSE:CRL) gapped down before the market opened on Tuesday . The stock had previously closed at $190.14, but opened at $179.87. Charles River Laboratories International shares last traded at $179.71, with a volume of 207,216 shares trading hands.

Analyst Ratings Changes

A number of equities research analysts have issued reports on CRL shares. Robert W. Baird decreased their price target on shares of Charles River Laboratories International from $191.00 to $190.00 and set a “neutral” rating for the company in a report on Friday, September 20th. Redburn Atlantic began coverage on shares of Charles River Laboratories International in a research report on Monday, October 14th. They issued a “sell” rating and a $151.00 price target for the company. Evercore ISI increased their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. Bank of America dropped their price target on shares of Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating for the company in a research report on Friday, December 13th. Finally, TD Cowen increased their price target on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the stock a “hold” rating in a research report on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating and three have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $214.00.

Charles River Laboratories International Trading Down 4.3 %

The business’s 50-day moving average price is $192.56 and its two-hundred day moving average price is $198.95. The company has a market capitalization of $8.51 billion, a P/E ratio of 20.83, a PEG ratio of 6.62 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a current ratio of 1.48 and a quick ratio of 1.14.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, topping analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. During the same period last year, the business posted $2.72 earnings per share. The firm’s quarterly revenue was down 1.6% on a year-over-year basis. As a group, analysts forecast that Charles River Laboratories International, Inc. will post 10.18 EPS for the current fiscal year.

Insider Activity

In other news, Director Richard F. Wallman sold 6,621 shares of Charles River Laboratories International stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares of the company’s stock, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.30% of the company’s stock.

Institutional Trading of Charles River Laboratories International

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new stake in Charles River Laboratories International in the 3rd quarter valued at about $601,000. JPMorgan Chase & Co. raised its position in shares of Charles River Laboratories International by 21.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company’s stock valued at $95,086,000 after buying an additional 85,759 shares in the last quarter. State Street Corp increased its position in Charles River Laboratories International by 2.0% during the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock worth $419,601,000 after purchasing an additional 41,421 shares in the last quarter. Janus Henderson Group PLC increased its position in Charles River Laboratories International by 7.6% in the 3rd quarter. Janus Henderson Group PLC now owns 46,018 shares of the medical research company’s stock valued at $9,064,000 after acquiring an additional 3,268 shares during the period. Finally, Neo Ivy Capital Management acquired a new position in Charles River Laboratories International in the 3rd quarter valued at approximately $966,000. Institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).